Research programme: selective nicotinic acetylcholine receptor agonists - Suven Life Sciences

Drug Profile

Research programme: selective nicotinic acetylcholine receptor agonists - Suven Life Sciences

Alternative Names: SUVN F90101; SUVN-F91201

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Suven Life Sciences
  • Class
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders
  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in India
  • 29 Dec 2015 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds for the treatment of major depressive disorder in Europe and Macau
  • 19 Aug 2014 Preclinical trials in Metabolic disorders in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top